Hemostemix (HEM) Insider Trading & Ownership C$0.12 -0.01 (-4.00%) As of 03:59 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisChartHeadlinesInsider Trades Hemostemix (CVE:HEM) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage10.43%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)C$30,480.00Number OfInsiders Selling(Last 12 Months)2Amount OfInsider Selling(Last 12 Months)C$40,600.68 Get HEM Insider Trade Alerts Want to know when executives and insiders are buying or selling Hemostemix stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address HEM Insider Buying and Selling by Quarter Remove Ads Hemostemix Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails3/6/2025Peter Alan LaceyDirectorBuy200,000C$0.15C$30,000.002/26/2025Peter Alan LaceyDirectorSell96,464C$0.18C$16,881.2010/18/2024Thomas SmeenkDirectorSell28,093C$0.08C$2,106.9810/8/2024Thomas SmeenkDirectorSell332,500C$0.07C$21,612.508/21/2024Thomas SmeenkDirectorBuy2,000C$0.04C$80.006/25/2024Thomas SmeenkDirectorBuy10,000C$0.04C$400.00 (Data available from 1/1/2013 forward) HEM Insider Trading Activity - Frequently Asked Questions Who is on Hemostemix's Insider Roster? The list of insiders at Hemostemix includes Peter Alan Lacey, and Thomas Smeenk. Learn more on insiders at HEM. What percentage of Hemostemix stock is owned by insiders? 10.43% of Hemostemix stock is owned by insiders. Learn more on HEM's insider holdings. Which Hemostemix insiders have been buying company stock? The following insiders have purchased HEM shares in the last 24 months: Peter Alan Lacey (C$30,000.00), and Thomas Smeenk (C$4,540.00). How much insider buying is happening at Hemostemix? Insiders have purchased a total of 270,000 HEM shares in the last 24 months for a total of C$34,540.00 bought. Which Hemostemix insiders have been selling company stock? The following insiders have sold HEM shares in the last 24 months: Peter Alan Lacey (C$16,881.20), and Thomas Smeenk (C$23,719.48). How much insider selling is happening at Hemostemix? Insiders have sold a total of 457,057 Hemostemix shares in the last 24 months for a total of C$40,600.68 sold. Hemostemix Key ExecutivesMr. Thomas A. Smeenk B.A. (Age 62)BA Hons, Co-Founder, President, CEO & Director Compensation: $308kMs. Christina Wu CPAInterim Chief Financial OfficerMr. Peter PavlinVice President of OperationsDr. Fraser C. Henderson Sr.M.D., Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies ONC Insider Transactions MDNA Insider Transactions TH Insider Transactions SVA Insider Transactions MBX Insider Transactions ATE Insider Transactions KNE Insider Transactions RVX Insider Transactions IOT Insider Transactions QPT Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Companies Buying Back Stock—Why It MattersInsider Scoop: 4 Stocks Insiders Are Buying and Selling2 Stocks Insiders Are Buying and 1 They're Selling3 Stocks With Robust Growth Outlooks Insiders Are BuyingMETA Stock: Insider Selling Ramps Up—What It Means for Investors This page (CVE:HEM) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'Trump Orders ‘National Digital Asset Stockpile’ THIS could be the coin they choose…Crypto 101 Media | SponsoredDOGE’s Next Move: Not what you thinkDonald Trump, Elon Musk and the Department of Government Efficiency have kept their word. Moving even faste...Weiss Ratings | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemostemix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemostemix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
